Zhang Xu, Jiang Peng, Wang Chaojun
Department of Urology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Front Oncol. 2023 Sep 7;13:1127637. doi: 10.3389/fonc.2023.1127637. eCollection 2023.
Prostate cancer is the only human malignancy that generates predominantly osteoblastic bone metastases, and osteoblastic bone metastases account for more than 90% of osseous metastases of prostate cancer. Prostate-specific antigen (PSA) plays an important role in the osteoblastic bone metastasis of prostate cancer, which can promote osteomimicry of prostate cancer cells, suppress osteoclast differentiation, and facilitate osteoblast proliferation and activation at metastatic sites. In the meantime, it can activate osteogenic factors, including insulin-like growth factor, transforming growth factor β2 and urokinase-type plasminogen activator, and meanwhile suppress osteolytic factors such as parathyroid hormone-related protein. To recapitulate, PSA plays a significant role in the osteoblastic predominance of prostate cancer bone metastasis and bone remodeling by regulating multiple cells and factors involved in osseous metastasis.
前列腺癌是唯一主要产生成骨性骨转移的人类恶性肿瘤,而成骨性骨转移占前列腺癌骨转移的90%以上。前列腺特异性抗原(PSA)在前列腺癌的成骨性骨转移中起重要作用,它可以促进前列腺癌细胞的骨模拟,抑制破骨细胞分化,并促进转移部位的成骨细胞增殖和活化。同时,它可以激活包括胰岛素样生长因子、转化生长因子β2和尿激酶型纤溶酶原激活剂在内的成骨因子,同时抑制甲状旁腺激素相关蛋白等溶骨因子。概括地说,PSA通过调节参与骨转移的多种细胞和因子,在前列腺癌骨转移的成骨优势和骨重塑中发挥重要作用。